Reactogenicity Differences between COVID-19 Vaccines: A Pro spective Observational Study in the United States and Canada

Matthew D. Rousculp ^{1,*}, Kelly Hollis ², Ryan Ziemiecki ², Dawn Odom ², Anthony M. Marchese ¹, Mitra Montazeri ¹,
 Shardul Odak ², Laurin Jackson ², Hadi Beyhaghi¹, and Seth Toback ¹

- 5 ¹ Novavax, Inc. Gaithersburg, MD 20878, USA; mrousculp@novavax.com (M.D.R.); amarchese@novavax.com (A.M.M.);
- 6 <u>mmontazeri@novavax.com</u> (M.M.); <u>hbeyhaghi@novavax.com</u> (H.B.); <u>stoback@novavax.com</u> (S.T.)
- 7 ² RTI Health Solutions, Research Triangle Park, NC 27709, USA; <u>khollis@rti.org</u> (K.H.); <u>rziemiecki@rti.org</u> (R.Z.); <u>dodom@rti.org</u> (D.O.);
- 8 <u>sodak@rti.org</u> (S.O.); <u>gibson@rti.org</u> (L.J.)
- 9 * Correspondence: mrousculp@novavax.com
- 10 Abstract: Participants in studies investigating COVID-19 vaccines commonly report reactogenicity events, and concerns about side
- 11 effects may lead to reluctance to receive updated COVID-19 vaccinations. A real-world, post hoc analysis, observational
- 12 2019nCoV-406 study, was conducted to examine reactogenicity within the first 2 days after vaccination with either a protein-based
- 13 vaccine (NVX-CoV2373) or an mRNA vaccine (BNT162b2 or mRNA-1273) in individuals who previously completed a primary series.
- 14 Propensity score adjustments were conducted to address potential confounding. The analysis included 1130 participants who re-
- 15 ceived a post-primary series dose of NVX-CoV2373 (n = 303) or an mRNA vaccine (n = 827) during the study period. Within the first
- 16 2 days after vaccination, solicited systemic reactogenicity events (adjusted) were reported in 60.5% of participants who received
- 17 NVX-CoV2373 compared with 84.3% of participants who received an mRNA vaccine; moreover, 33.9% and 61.4%, respectively,
- 18 reported \geq 3 systemic reactogenicity symptoms. The adjusted mean (95% Cl) number of systemic symptoms was 1.8 (1.6–2.0) and
- 19 3.2 (3.0-3.4), respectively. Local reactogenicity events (adjusted) were reported in 73.4% and 91.7% of participants who received
- 20 NVX-CoV2373 and mRNA vaccines, respectively; the adjusted mean (95% Cl) number of local symptoms was 1.5 (1.33–1.61) and 2.4
- 21 (2.31–2.52), respectively. These results support the use of adjuvanted, protein-based NVX-CoV2373 as an immunization option with
- 22 low reactogenicity.
- 23
- 24 Keywords: Booster, COVID-19, reactogenicity, real-world evidence, SARS-CoV-2, NVX-CoV2373, mRNA
- 25

26

27 1. Introduction

To date, multiple types of vaccines have been developed to protect against COVID-19. As the need for additional COVID-19 vaccination continues, messenger RNA (mRNA)–based and protein-based vaccines are expected to be the most widely utilized platforms. The mRNA COVID-19 vaccines developed by Pfizer (BNT162b2) and Moderna (mRNA-1273) are approved for use in the United States (US) and Canada [1-3], and a protein-based vaccine formulated with saponin-based Matrix-M[™] adjuvant developed by Novavax is authorized for use in the US and approved for use in Canada [3,4].

Participants in COVID-19 vaccine clinical trials have commonly reported mild and transient reactogenicity events 34 35 within 7 days of receiving a vaccine, with many events resolving within 2 days post-vaccination [5-11]. These symptoms include local (injection-site) reactions (pain, tenderness, erythema, or swelling) or systemic reactions 36 (fatigue, malaise, muscle pain, joint pain, nausea/vomiting, headache, or fever), which may increase with subsequent 37 doses of a COVID-19 vaccine [6,9-12]. Local and systemic reactions are also commonly reported for immunizations 38 targeting infectious diseases other than COVID-19 (e.g., influenza or shingles) [13,14]. Of note, studies comparing 39 reactogenicity have generally found a higher incidence of local and systemic events following receipt of mRNA 40COVID-19 vaccines compared with influenza and other non-COVID-19 vaccines, as well as a higher frequency of 41reactogenicity-associated medication use, sick leave, and doctor's visits [15,16]. 42

COVID-19 vaccine-related reactogenicity events can affect work and other daily activities, leading to 43 44 absenteeism from work [17,18] and presenteeism [17,19], as well as vaccine hesitancy [20-24]. Indeed, concern over 45 vaccine side effects was found to be the most common reason for refusing an updated COVID-19 vaccine [24]. The 2019nCoV-406 study surveyed participants in the US and Canada who were receiving a COVID-19 vaccine to compare 46 how reactogenicity impacted work and other daily activities [17]. Findings suggest that in the 6 days following 47 vaccination, recipients of the protein-based NVX-CoV2373 vaccine had lower unadjusted reactogenicity rates and had 48 trended toward less overall impairment relative to recipients of mRNA vaccines (BNT162b2 and mRNA-1273). We also 49 50observed that over 90% of the most frequently occurring solicited reactogenicity events were reported within the first 2 days after vaccination. Here, we present an additional analysis of the 2019nCoV-406 study, including adjustment for 51 52 potential confounding, to more closely examine reactogenicity within 2 days of receiving an authorized/approved 53 COVID-19 vaccine in previously vaccinated participants.

54

55 2. Materials and Methods

56 2.1 Study Design and Participants

The prospective, noninterventional, observational 2019nCoV-406 study investigated the impact of common 57 reactogenicity events from the COVID-19 vaccine on absenteeism, presenteeism, and work productivity loss [17]. 58 Briefly, the study enrolled working adults aged 18 to <65 years in the US and Canada who voluntarily received an au-59 60 thorized/approved primary series or booster (post-primary series) dose of a COVID-19 vaccine. As this was an observational study, participants selected the COVID-19 vaccine type they wanted to receive. A booster dose was defined as 61 any COVID-19 dose received after completion of a primary COVID-19 vaccination series, regardless of prior vaccine 62 type used or prior COVID-19 disease status. Post-primary series vaccinations included NVX-CoV2373 (5 µg recombi-63 nant spike protein co-formulated with 50 µg of Matrix-M adjuvant) or an mRNA vaccine (BTN162b2 [30 µg] and 64 mRNA-1273 [50 µg]). Participants completed baseline/screening questionnaires on the day of their vaccine (day 0) and 65 a daily diary for the following 6 days that included a Vaccine Symptoms Diary. Further details on participant inclusion 66 67 criteria and study methods are available in the prior publication [17]. Written informed consent was provided by each participant prior to receipt of their requested vaccine dose and survey completion. 68

69

70 2.2 Objectives

The descriptive/comparative goal of this post hoc analysis was to determine the difference in local or systemic reactogenicity events occurring within the first 2 days after receipt of an NVX-CoV2373 vaccine versus an mRNA COVID-19 vaccine, administered after completion of any primary vaccination series.

74

75 2.3 Assessments

The Vaccine Symptoms Diary measured 11 solicited, participant-reported local/systemic symptoms over a 24-h recall period. Solicited systemic reactogenicity symptoms were fever, fatigue, malaise, muscle pain, joint pain, nausea/vomiting, and headache. Solicited local reactogenicity symptoms included pain, tenderness, swelling, and redness at the injection site. All symptoms were recorded using a 0-to-3 response scale based on the worst level of reactogenicity severity experienced, with responses categorized as 0 (no symptom present), 1 (mild/no interference with activity), 2 (moderate/interferes with activity), and 3 (severe/significant interference with activity). A participant

was considered to have experienced a reactogenicity symptom if they reported a severity of at least grade 1. This
 analysis used data from the 2 days immediately following vaccination.

84

85 2.4 Statistics

Analyses of reactogenicity in the 2 days following vaccination were completed in the booster dose population (hereafter referred to as the post-primary series population), which consisted of participants who received any post-primary series dose of an approved/authorized COVID-19 vaccine, regardless of which vaccine type was used for prior doses or if they had previously had COVID-19. Due to low numbers receiving other vaccine types, only data related to NVX-CoV2373 or the mRNA vaccines (BNT162b2 and mRNA-1273) were included in this analysis. Estimation of the sample size required to power the primary objectives in the main study was described previously [17].

Results are presented by vaccine groups composed of participants who received NVX-CoV2373 and participants who received BNT162b2 or mRNA-1273, referred to as the mRNA vaccine group. Findings are also presented in subgroups for the different mRNA vaccines (BNT162b2 or mRNA-1273) and country (US or Canada).

Analyses are presented separately for systemic and local reactogenicity. The proportions of participants with any 95 systemic/local reactogenicity and with individual systemic/local reactogenicity events, mean numbers of system-96 ic/local events, and the proportion of participants with ≥ 3 systemic events are presented as comparative analyses. 97 98 Comparative analyses were adjusted to address potential confounding using inverse probability of treatment 99 weighting (IPTW). As described previously [17], each participant was assigned a propensity score based on a select group of demographic and clinical characteristics identified using standardized differences. The present analysis used 100 101 the following covariates in the IPTW model: country (US vs Canada), prior COVID-19 diagnosis (yes vs no), race (Asian, 102 White), job category (professional), work at home (yes, no, or prefer not to answer), gender identity (male, female), and scheduled to work in the next 24 h (yes vs no). The comparative analyses were weighted using stabilized inverse 103 104 probability of treatment weights. Because of the sample size limitation, event severity and all subgroup analyses were analyzed descriptively. All results use the overall participant post-primary series sample. Results were not adjusted for 105 106 multiple comparisons.

107 **3. Results**

108 3.1 Participants

The 2019nCoV-406 study was conducted between July 2022 and March 2023. The post-primary series popula-109 tion included 1130 participants, 303 of whom received NVX-CoV2373 and 827 who received an mRNA vaccine during 110the study period. Baseline demographics and clinical characteristics were generally balanced between vaccine groups, 111 as reported previously [17]; however, some differences between the NVX-CoV2373 and mRNA vaccine groups were 112 observed related to ethnicity (Table 1). A higher proportion of Hispanic, Latin American, or Latinx (50.8%) and White 113 (50.2%) participants received NVX-CoV2373 versus an mRNA vaccine (25.0% and 33.6%, respectively). By contrast, 114 more Asian (22.9%) and Native Hawaiian or Pacific Islander (9.1%) participants received an mRNA vaccine versus 115 NVX-CoV2373 (13.2% and 2.0%, respectively). Medical conditions that put participants at high risk for severe 116 COVID-19 were relatively low in both groups (NVX-CoV2373, 6.3%; mRNA, 5.4%). Of those participants who received 117 118 NVX-CoV2373, more did so as a first (60.7%) versus second (39.3%) dose after completion of the primary series. Al-119 ternatively, of those who received an mRNA vaccine, more received this as a second (62.6%) versus first (37.4%) post-primary series dose. 120

	Post–prin	nary series				
	population [17]		U	US		ada
Parameter	NVX-CoV2373 (n = 303)	mRNA vaccine ^a	NVX-CoV2373 (n = 205)	mRNA vaccine ^a	NVX-CoV2373 (n = 98)	mRNA vaccine ^a
Age, mean (SD) years	38.9 (11.8)	(n = 827) 40.1 (13.0)	39.4 (12.0)	(n = 426) 42.6 (13.4)	37.9 (11.2)	(n = 401) 37.5 (12.0)
Gender identity, n (%)						
Female	156 (51.5)	469 (56.7)	109 (53.2)	243 (57.0)	47 (48.0)	226 (56.4)
Male	142 (46.9)	355 (42.9)	95 (46.3)	182 (42.7)	47 (48.0)	173 (43.1)
Genderfluid	1 (0.3)	0	0	0	1 (1.0)	0
Nonbinary	2 (0.7)	3 (0.4)	0	1 (0.2)	2 (2.0)	2 (0.5)
Prefer not to answer	2 (0.7)	0	1 (0.5)	0	1 (1.0)	0
Race/ethnicity ^b , n (%)						
African American or Black	33 (10.9)	77 (9.3)	27 (13.2)	67 (15.7)	6 (6.1)	10 (2.5)
Asian ^c	40 (13.2)	189 (22.9)	8 (3.9)	21 (4.9)	32 (32.7)	168 (41.9)
Hispanic, Latin American, or Latinx	154 (50.8)	207 (25.0)	145 (70.7)	197 (46.2)	9 (9.2)	10 (2.5)
Middle Eastern or North African ^d	5 (1.7)	21 (2.5)	2 (1.0)	2 (0.5)	3 (3.1)	19 (4.7)

121 **Table 1.** Baseline demographics and clinical characteristics of study participants by region

Native Hawaiian or Pacific Islander ^e	6 (2.0)	75 (9.1)	2 (1.0)	0	4 (4.1)	75 (18.7)
White	152 (50.2)	278 (33.6)	106 (51.7)	157 (36.9)	46 (46.9)	121 (30.2)
Other ^f	11 (3.6)	22 (2.7)	6 (2.9)	9 (2.1)	5 (5.1)	13 (3.2)
Prior COVID-19 diagnosis, n (%)	119 (39.3)	433 (52.4)	67 (32.7)	239 (56.1)	52 (53. 1)	194 (48.4)
Medical condition that puts participant at						
high risk for severe COVID-19 ^b , n (%)						
Diabetes	6 (31.6)	21 (46.7)	2 (1.0)	15 (3.5)	4 (4.1)	6 (1.5)
Hypertension	7 (36.8)	13 (28.9)	5 (2.4)	10 (2.3)	2 (2.0)	3 (7.5)
Heart disease	2 (10.5)	8 (17.8)	1 (6.7)	8 (1.9)	1 (1.0)	0
Respiratory conditions	5 (26.3)	11 (24.4)	4 (2.0)	7 (1.6)	1 (1.0)	4 (1.0)
Other	5 (26.3)	13 (28.9)	4 (2.0)	10 (2.3)	1 (1.0)	3 (0.7)
Booster dose, n (%)						
First	184 (60.7)	309 (37.4)	167 (81.5)	266 (62.4)	17 (17.3)	43 (10.7)
Second or later	119 (39.3)	518 (62.6)	38 (18.5)	160 (37.6)	81 (82.7)	358 (89.3)
mRNA vaccine type, n (%)						
Monovalent	-	652 (78.8)	-	401 (94.1)	-	251 (62.6)
Bivalent	-	175 (21.2)	-	25 (5.9)	-	150 (37.4)

Baseline demographics and clinical characteristics for the post-primary series population have been published previously [17]. SD = standard deviation. ^aIndividuals received either BNT162b2 or mRNA-1273. ^bThe categories for these variables were not mutually exclusive (participants could have listed more than one). ^cIncludes participants who identified as Chinese, South Asian (e.g., East Indian, Pakistani, or Sri Lankan), Southeast Asian (e.g., Vietnamese, Cambodian, Laotian, or Thai), Korean, or Japanese. ^dIncludes participants who identified as Middle Eastern, North African, Arab, or West Asian (e.g., Iranian or Afghan). ^eIncludes participants who identified as Native Hawaiian, Pacific Islander, or Filipino. ^fRace/ethnicity categories with fewer than 20 responses are captured in the "other" category and include: Alaska Native, American Indian, or Native American participants (total n = 6); race or ethnicity not listed (n = 16); and prefer not to answer (n = 11).

129

Of the 1130 participants in the post-primary series population, 631 participants (NVX-CoV2373, n = 205; mRNA, n = 426) were from the US and 499 (NVX-CoV2373, n = 98; mRNA, n = 401) were from Canada (**Table 1**). Baseline demographics and characteristics of participants from the US and Canada were generally similar to those observed in the overall post-primary series population. Most participants with a Hispanic, Latin American, or Latinx ethnicity came from the US and most participants with an Asian or Native Hawaiian or Pacific Islander ethnicity came from Canada.

136 3.2 Systemic Reactogenicity

Within the first 2 days after vaccination, solicited systemic reactogenicity events were reported in 56.4% of participants who received NVX-CoV2373 and 84.4% of participants who received an mRNA vaccine (BNT162b2: 84.5%; mRNA-1273: 84.3%). After IPTW adjustment, 60.5% of participants who received the NVX-CoV2373 reported solicited systemic reactogenicity events compared with 83.8% of participants who received an mRNA vaccine (**Figure 1**). Muscle pain (NVX-CoV2373: 41.6%; mRNA vaccine: 72.3%), fatigue (47.8% and 66.5%, respectively), and malaise (34.5% and 57.7%, respectively) were the most common systemic events in each vaccine group.



Figure 1. Rates of overall and individual solicited systemic reactogenicity events within 2 days of post-primary-series vaccination (IPTW adjusted estimates). Results are presented for the post-primary series population. CI, confidence interval; IPTW, inverse probability of treatment weighting.

147

143

Participants who received NVX-CoV2373 reported a mean number (SD) of 1.8 (2.0) systemic events, whereas those who received an mRNA vaccine reported a mean of 3.2 (2.1) systemic events (**Table 2**). Adjusting for confounding by IPTW led to similar results, with mean numbers of events (95% Cl) of 1.8 (1.6–2.0) for the NVX-CoV2373 group and 3.2 (3.0–3.4) for the mRNA vaccine group (**Figure 2**). Markedly fewer participants who received NVX-CoV2373 reported three or more systemic reactogenicity events than those who received an mRNA vaccine (adjusted values [95% Cl]: NVX-CoV2373, 33.9% [28.7–39.1%]; mRNA vaccine, 61.4% [58.1–64.8%]).

155 **Table 2.** Descriptive analysis of systemic reactogenicity events in the overall population and by mRNA vaccine subgroup (unadjust-

156 ed)

	NVX-CoV2373	mRNA vaccine	5114		
	(n = 303)	(n =827)	mRNA vacc	ine subgroup	
			BNT162b2	mRNA-1273	
			(n = 502)	(n = 325)	
Nedian (range)	1 (0-7)	3 (0–7)	3 (0–7)	4 (0-7)	
lumber of events, n (%)					
No systemic reactogenicity events	132 (43.6)	129 (15.6)	78 (15.5)	51 (15.7)	
1	41 (13.5)	91 (11.0)	62 (12.4)	29 (8.9)	
2	34 (11.2)	98 (11.9)	73 (14.5)	25 (7.7)	
3	26 (8.6)	108 (13.1)	69 (13.7)	39 (12.0)	
4	26 (8.6)	140 (16.9)	81 (16.1)	59 (18.2)	
5	26 (8.6)	128 (15.5)	72 (14.3)	56 (17.2)	
6	11 (3.6)	89 (10.8)	48 (9.6)	41 (12.6)	
7	7 (2.3)	44 (5.3)	19 (3.8)	25 (7.7)	
everity, n (%)					
No reactogenicity symptoms reported	132 (43.6)	129 (15.6)	78 (15.5)	51 (15.7)	
Mild/no interference with activities	87 (28.7)	290 (35.1)	184 (36.7)	106 (32.6)	
Moderate/interfered with activities	62 (20.5)	288 (34.8)	177 (35.3)	111 (34.2)	
Severe/significant interference with activities	22 (7.3)	120 (14.5)	63 (12.5)	57 (17.5)	

157 Table shows descriptive data summarizing systemic reactogenicity events reported within 2 days of receipt of a post-primary series vaccination in

158 the post-primary series population. All values are unadjusted.





Figure 2. Summary of solicited systemic reactogenicity events within 2 days of post-primary series vaccination (IPTW adjusted estimates). Post-primary series population. CI, confidence interval; IPTW, inverse probability of treatment weighting.

With respect to event severity, a lower proportion (unadjusted) of participants who received NVX-CoV2373 reported a moderate or severe/significant systemic event within 2 days of vaccination compared with participants who received an mRNA vaccine (27.7% [84/303] vs 49.3% [408/827]). Mild events were also reported in lower proportions of participants who received NVX-CoV2373 (28.7%) compared with those who received an mRNA vaccine (35.1%).

The mean (SD) number of systemic events was similar whether participants received BNT162b2 (3.0 [2.1]) or mRNA-1273 (3.5 [2.2]). Similarly, the proportion of participants reporting any systemic event was 84.5% (424/502) and 84.3% (274/325), respectively. However, a higher proportion of participants receiving mRNA-1273 reported three or more systemic reactogenicity events (unadjusted; 67.7% [220/325]) compared with BNT162b2 (57.6% [289/502]). The proportion of participants reporting moderate-to-severe systemic events was 51.7% (168/325) and 47.8% (240/502) with mRNA-1273 and BNT162b2, respectively (**Table 2**).

When assessed by country, unadjusted proportions of systemic reactogenicity events in the US were lower in participants who received NVX-CoV2373 (48.5%) compared with participants who received an mRNA vaccine (79.1%) (**Table 3**). Corresponding proportions tended to be higher for both vaccine types in Canadian participants (NVX-CoV2373: 72.5%; mRNA: 90.0%). Regardless of country, participants who received NVX-CoV2373 reported fewer systemic reactogenicity events (mean [SD]: US, 1.6 [2.1]; Canada, 2.1 [2.0]) than those who received an mRNA vaccine

(mean [SD]: US, 3.1 [2.3]; Canada, 3.3 [1.9]). Similarly, regardless of country, fewer participants who received
NVX-CoV2373 reported three or more events (US: 29.8% [61/205]; Canada: 35.7% [35/98]) compared with those who
received an mRNA vaccine (US: 58.2% [248/426]; Canada: 64.8% [260/401]) and fewer participants who received
NVXCoV2373 reported moderate-to-severe events (US: 22.0% [45/205]); Canada: 39.8% [39/98]) compared with those
who received an mRNA vaccine (US: 45.5% [194/426]; Canada: 53.4% [214/401]).

183

184 **Table 3.** Descriptive analysis of systemic reactogenicity events by country (unadjusted)

	ι	JS	Car	ada
	NVX-CoV2373	mRNA vaccine	NVX-CoV2373	mRNA vaccine
	(n = 205)	(n = 426)	(n = 98)	(n = 401)
Mean (SD)	1.6 (2.1)	3.1 (2.3)	2.1 (2.0)	3.3 (1.9)
Median (range)	0 (0–7)	3 (0–7)	2 (0–7)	4 (0-7)
Any systemic event, n (%)	100 (48.5)	337 (79.1)	71 (72.5)	361 (90.0)
Number of events, n (%)				
No systemic reactogenicity events	105 (51.2)	89 (20.9)	27 (27.6)	40 (10.0)
1	23 (11.2)	41(9.6)	18 (18.4)	50 (12.5)
2	16 (7.8)	48(11.3)	18 (13.4)	50 (12.5)
3	18 (8.8)	52 (12.2)	8 (8.2)	56 (14.0)
4	12 (5.9)	57 (13.4)	14 (14.3)	83 (20.7)
5	20 (9.8)	63(14.8)	6 (6.1)	65 (16.2)
6	6 (2.9)	45 (10.6)	5 (5.1)	44 (11.0)
7	5 (2.4)	31(7.3)	2 (2.0)	12 (3.2)
Severity, n (%)				
No reactogenicity symptoms reported	105 (51.2)	89 (20.9)	27 (27.6)	40 (10.0)
Mild/no interference with activities	55 (26.8)	143 (33.6)	32 (32.7)	147 (36.7)
Moderate/interfered with activities	31 (15.1)	139 (32.5)	31 (31.6)	149 (37.2)
Severe/significant interference with activities	14 (6.8)	55 (12.9)	8 (8.2)	65 (16.2)

185 Table shows descriptive data summarizing systemic reactogenicity events reported within 2 days of receipt of a post-primary series vaccination in 186 the post-primary series population. All values are unadjusted.

187

188 **3.3** Local Reactogenicity

Similar to systemic reactogenicity, a lower proportion of participants who received NVX-CoV2373 (68.3%) expe-189 rienced at least one solicited local reactogenicity event, compared with those who received an mRNA vaccine (91.9%; 190 191 BNT162b2, 92.6%; mRNA-1273, 90.8%). After IPTW adjustment, local reactogenicity events were estimated to be re-192 ported in 73.7% and 91.7% of participants who received a booster dose of NVX-CoV2373 and mRNA vaccine, respec-193 tively (Figure 3). This trend in differences continued, with the overall frequency of each individual event occurring in a 194 higher proportion of participants in the mRNA vaccine versus NVX-CoV2373 group. For both the NVX-CoV2373 and 195 mRNA vaccine groups, the most common solicited local events were pain (61.7% and 84.8%, respectively) and ten-196 derness (65.4% and 87.9%, respectively) at the injection site.





Figure 3. Overall and individual solicited local reactogenicity events within 2 days of post-primary series vaccination (IPTW
 adjusted estimates). Post-primary series population. Cl, confidence interval; IPTW, inverse probability of treatment
 weighting.

202

The mean number (SD) of reported local reactogenicity events per individual was 1.5 (1.3) for participants who received NVX-CoV2373 and 2.4 (1.1) for those who received an mRNA vaccine. Mean (95% Cl) adjusted numbers were 1.5 (1.3–1.6) and 2.4 (2.3–2.5), respectively. Compared with the NVX-CoV2373 group (21.1%), the proportion (unadjusted) of participants reporting moderate or severe/significant local reactogenicity events was 2.5-fold higher for participants in the mRNA vaccine group (52.0%) (**Table 4**).

209 Table 4. Descriptive analysis of local reactogenicity events in the overall population and by mRNA vaccine subgroup (unadjusted)

	NVX-CoV2373	mRNA vaccine	mRNA vaccine subgroup	
	(n = 303)	(n = 827)	BNT162b2	mRNA-1273
			(n = 502)	(n = 325)
Лedian (range)	2 (0-4)	2 (0-4)	2 (0–4)	3 (0-4)
lumber of events, n (%)				
No systemic reactogenicity events	96 (31.7)	67 (8.1)	37 (7.4)	30 (9.2)
1	51 (16.8)	57 (6.9)	38 (7.6)	19 (5.8)
2	98 (32.3)	328 (39.7)	227 (45.2)	101 (31.1)
3	33 (10.9)	216 (26.1)	130 (25.9)	86 (26.5)

4	25 (8.3)	159 (19.2)	70 (13.9)	89 (27.4)	
Severity, n (%)					
No reactogenicity symptoms reported	96 (31.7)	67 (8.1)	37 (7.4)	30 (9.2)	
Mild/no interference with activities	143 (47.2)	330 (39.9)	222 (44.2)	108 (33.2)	
Moderate/interfered with activities	57 (18.8)	338 (40.9)	200 (39.8)	138 (42.5)	
Severe/significant interference with activities	7 (2.3)	92 (11.1)	43 (8.6)	49 (15.1)	

210 Table shows descriptive data summarizing local reactogenicity events reported within 2 days of receipt of a post-primary series vaccination in the

211 post-primary series population. All values are unadjusted.

212

Reporting of local events was generally similar whether participants received BNT162b2 or mRNA-1273 (**Table 4**). The proportion (unadjusted) of participants reporting any local event was 92.6% (465/502) for BNT162b2 and 90.8% (295/325) for mRNA-1273. The mean number (SD) of local events reported was similar between subgroups (2.3 [1.0] and 2.6 [1.2], respectively); however, the proportion of participants who reported moderate or severe local events was higher in recipients of mRNA-1273 (57.5% [187/325]) than recipients of BNT162b2 (48.4% [243/502]).

In both the US and Canada, proportions (unadjusted) of local reactogenicity events were lower in participants 218 who received NVX-CoV2373 compared with participants who received an mRNA vaccine, with events reported at a 219 220 lower frequency in US versus Canadian participants (US: NVX-CoV2373, 62.4% vs mRNA, 88.3%; Canada: NVX-CoV2373, 80.6% vs mRNA, 95.8%) (Table 5). The mean number of local reactogenicity events reported in the US 221 and Canada tended to follow the same pattern as the overall post-primary series population, with fewer events re-222 223 ported for those who received NVX-CoV2373 versus an mRNA vaccine. Similar to the overall population, regardless of country, lower proportions of participants who received NVX-CoV2373 reported moderate-to-severe local 224 225 reactogenicity events (US: 20.0% [41/205]; Canada: 23.5% [23/98]) compared with those who received an mRNA vaccine (US: 46.0% [196/426]; Canada: 58.4% [234/401]). 226

227 **Table 5.** Descriptive analysis of local reactogenicity events by country (unadjusted)

	l	US		da	
	NVX-CoV2373	mRNA vaccine	NVX-CoV2373	mRNA vaccine	
	(n = 205)	(n = 426)	(n = 98)	(n = 401)	
Mean (SD)	1.3 (1.3)	2.4 (1.3)	1.7 (1.2)	2.4 (1.0)	
Median (range)	1 (0-4)	2 (0-4)	2 (0–4)	2 (0-4)	
Any local event, n (%)	128 (62.4)	376 (88.3)	79 (80.6)	384 (95.8)	
Number of events, n (%)					
No local reactogenicity events	77 (37.6)	50 (11.7)	19 (19.4)	17 (4.2)	
1	33 (16.1)	36 (8.5)	18 (18.4)	21 (5.2)	

2	59 (28.8)	133 (31.2)	39 (39.8)	195 (48.6)
3	20 (9.8)	108 (25.4)	12 (13.3)	108 (26.9)
4	16 (7.8)	99 (23.2)	9 (9.2)	60 (15.0)
Severity, n (%)				
No reactogenicity symptoms reported	77 (37.6)	50 (11.7)	19 (19.4)	17 (4.2)
Mild/no interference with activities	87 (42.4)	180 (42.3)	56 (57.1)	150 (37.4)
Moderate/interfered with activities	37 (18.1)	147 (34.5)	20 (20.4)	191 (47.6)
Severe/significant interferences with activities	4 (2.0)	49 (11.5)	3 (3.1)	43 (10.7)

228 Table shows descriptive data summarizing local reactogenicity events reported within 2 days of receipt of a post-primary series vaccination in the

229 post-primary series population. All values are unadjusted.

230 4. Discussion

In this post hoc analysis of the 2019nCoV-406 study, participants who received NVX-CoV2373 after completing a 231 primary vaccination series reported fewer and less severe local and systemic reactogenicity symptoms in the 2 days 232 following vaccination compared with those who received an mRNA vaccine after completing a primary vaccination 233 series. These real-world data provide a better understanding of reactogenicity events associated with the two 234 COVID-19 vaccine platforms (protein-based and mRNA) received in the US and Canada. In the 2 days following 235 vaccination, local and systemic reactogenicity events were more commonly reported in participants who received an 236 mRNA vaccine than in those who received NVX-CoV2373. The proportions of participants reporting the most common 237 local (injection site pain and tenderness) and systemic (muscle pain, fatigue, and malaise) reactogenicity events were 238 higher among those who received an mRNA vaccine (>84% and >57%, respectively) than among those who received 239 NVX-CoV2373 (up to 65% and up to 48%, respectively). In addition, mRNA vaccine recipients were more likely to 240 241 report experiencing three or more systemic events or events with moderate-to-severe severity than participants who 242 received NVX-CoV2373. These findings are consistent regardless of the mRNA brand compared.

These data build on overall findings from the 2019nCoV-406 study [17] by focusing on the 2 days immediately 243 following receipt of a post-primary series vaccination and adjusting for potential confounding using IPTW. As noted 244 245 previously, this timing is of interest because over 90% of the most frequently occurring solicited reactogenicity events in the 2019nCoV-406 study were reported within the first 2 days. Similarly, multiple studies have shown that systemic 246 247 and local reactogenicity events are short-lived, with mean or median durations of 2 days or less for the most frequently reported solicited reactogenicity events [7-9,11]. The primary analysis from the 2019nCoV-406 study sug-248 249 gested a trend toward less overall work impairment with NVX-CoV2373 compared with the mRNA vaccines [17]. In 250 addition, greater proportions of participants who received an mRNA vaccine reported local and systemic

reactogenicity events compared with NVX-CoV2373. This post hoc analysis showed consistent findings for the 2 days after post-primary series vaccination, including when potential confounding related to differences in baseline and clinical characteristics were accounted for using IPTW.

Multiple studies have found greater reactogenicity of mRNA vaccines relative to other COVID-19 vaccine plat-254 forms, including adjuvanted protein-based vaccines such as NVX-CoV2373 [12,16,25-30]. While there are limitations 255 to direct comparisons between different studies, it is notable how closely these findings from the 2019nCoV-406 256 study mirror observations from the Oxford COV-BOOST trial and a National Institute for Allergy and Infectious Diseas-257 258 es and National Institutes of Health-funded booster study [26,27]. Results from this analysis of 2019nCoV-406 expand on previous reports [16,28,30] by focusing on the effects of vaccine doses administered after completion of primary 259 COVID-19 vaccination series. Additional COVID-19 vaccine dosing, whether as the second dose of the primary series or 260 261 as subsequent doses, can result in greater reactogenicity compared with the first injection [6,9,10], especially when receiving a heterologous booster [19,25,31]. Although the studies investigating reactogenicity in homologous and 262 heterologous booster doses were generally not powered to make comparisons between vaccine types, altogether 263 findings from 2019nCoV-406 and other studies suggest that NVX-CoV2373, when administered as a heterologous 264 265 booster, has less reactogenicity than mRNA vaccines when administered as a homologous or heterologous post-primary series dose [12,25,26,30]. This is especially relevant as most people in the US and Canada have received 266 267 a primary series of an mRNA vaccine. Concern about side effects is a primary reason for COVID-19 vaccine hesitancy 268 [22-24]. Accordingly, COVID-19 vaccines with lower rates of reactogenicity, which is suggested of heterologous use of NVX-CoV2373 by the present analysis and several descriptive studies [12,25,26,30], have the potential to decrease 269 vaccine hesitancy. This may be especially useful given the continued evolution of SARS-CoV-2 and recommendations 270 271 from public health authorities for annual updates to the COVID-19 vaccine strain composition [32-35], suggesting the potential need for seasonal COVID-19 vaccination, similar to influenza vaccination. 272

Comparison between the two mRNA vaccines showed that BNT162b2 (30 µg) tended to elicit fewer and slightly less severe systemic and local reactogenicity events than mRNA-1273 (50 µg). If making cross-study comparisons, it is important to note the vaccine doses investigated in the studies [12,25-28]. In particular, participants in COV-BOOST and the MixNMatch Study (DMID 21-0012) received a higher dose of mRNA-1273 (100 µg) than is currently approved [26,27]. However, mRNA-1273 was administered at the approved 50 µg dose [2] in the 2019nCoV-406 study, and rates of reactogenicity events observed with RNA-1273 were still higher than those observed with BNT162b2.

279 Limitations to the 2019nCoV-406 study have been previously reported [17] and are inherent to all noninterventional, real-world investigations. For example, study participants may not be representative of all popula-280 tions receiving COVID-19 vaccines. This may be due to the timing of the study relative to vaccine approv-281 al/authorization; the later authorization for use and availability of NVX-CoV2373 (winter/early spring 2023) relative to 282 that of mRNA vaccines (late summer/early fall 2022) may have created a temporal bias. Low enrollment at some study 283 sites likely led to the concentration of participants with particular demographics (e.g., race/ethnicity) or with access to 284 a specific type of vaccine. In addition, while availability of different vaccine types may have been defined by what was 285 286 available at the site, vaccines were selected by the participant, which could also introduce bias. Real-word studies using patient-reported outcomes are often associated with concerns regarding the completeness and accuracy of pa-287 tient reporting. While participants were instructed to complete the daily questions at the same time every day, it was 288 289 possible to access and complete the diaries within an 8-h period.

It is relevant to note that the study was not powered to evaluate reactogenicity and that the post hoc nature of 290 this analysis limits the conclusions that can be derived from the results. IPTW adjustments were made for the overall 291 post-primary dose population; however, adjusted analyses were not available for data reporting on severity or for the 292 293 mRNA vaccine and country subgroups. Results in the country subgroups were largely similar to those of the overall population, however some differences were observed. A higher proportion of participants in the US (32% [205/630]) 294 selected NVX-CoV2373 compared with participants in Canada (20% [98/499]); reactogenicity tended to be reported in 295 296 higher proportions of Canadian participants, regardless of the vaccine received, and the differences in reactogenicity reporting between NVX-CoV2373 and mRNA vaccine subgroups tended to be greater in participants in the US com-297 pared with those from Canada. Some of these findings may be limited by differences in adverse event reporting in the 298 299 US and Canada; however, reactogenicity was higher among recipients of mRNA vaccines compared with NVX-CoV2373 in both countries. Finally, the impact of post-primary series dose number (e.g., first vs second post-primary series 300 301 dose) relative to reactogenicity was not assessed.

The 2019nCoV-406 study provides data from a large, real-world population of participants receiving an additional dose of COVID-19 vaccine after completion of a primary vaccination series. Reactogenicity was captured in the same manner as in the phase 3 studies of COVID-19 vaccines, thereby strengthening the generalizability of these findings. Importantly, participants were enrolled at the time of their vaccination, with data collected daily, improving accuracy and limiting recall bias. In addition, this post hoc analysis used propensity score adjustments (i.e., IPTW) to reduce bias.

308 5. Conclusions

Considering the lower frequency and intensity of COVID-19 reactogenicity symptoms observed in this post hoc analysis of the real-world 2019nCoV-406 study, this analysis supports use of adjuvanted protein-based NVX-CoV2373 as an immunization option that has low reactogenicity. Future prospective studies are needed to confirm the observations reported here and to continue to examine the effects of age, sex, race/ethnicity, and even comorbidities on COVID-19 vaccine reactogenicity.

314

- Author Contributions: Conceptualization, K.H., D.O., H.B., and S.T.; methodology, M.D.R., K.H., R.Z., D.O., S.O., L.J., and S.T.; software, R.Z., S.O., and L.J.; validation, R.Z., D.O., S.O. and L.J.; formal analysis, M.D.R., K.H., R.Z., and D.O.; investigation, all authors; resources, M.D.R., A.M.M., M.M., H.B., and S.T.; data curation, R.Z., S.O., and L.J.; writing—original draft preparation, M.D.R., K.H., R.Z., D.O., S.O., L.J., and S.T.; writing—review and editing, all authors; visualization, R.Z., D.O., and A.M.M.; supervision, M.D.R. and S.T.; project administration, S.O. and L.J.; funding acquisition, M.D.R. and S.T. All authors have read and agreed to the published version of this manuscript.
- 321 Funding: This research was funded by Novavax, Inc., and the APC was funded by Novavax, Inc.
- 322 Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki and approved by
- the Institutional Review Board (or Ethics Committee) of Advarra (Approval notice MOD01579170, approved 24 February 2023).

324 Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

325

326 Data Availability Statement: Data are available on request due to privacy restrictions. The data presented in this study are availa-

327 ble in aggregate form on request to the corresponding author. The data are not publicly available due to privacy requirements.

328 Acknowledgments: Medical writing and editorial support were provided by Miranda Bader-Goodman, PhD, Meredith Kalish, MD,

329 CMPP, Kelly M. Fahrbach, PhD, CMPP, and Ebenezer M. Awuah-Yeboah, BS, of Ashfield MedComms, an Inizio company, and funded

330 by Novavax, Inc. The authors would like to thank Angela Miller for her operational involvement in the study.

331 Conflicts of Interest: MDR, AMM, ST, HB, and MM are employees of Novavax, Inc. and may hold stock in Novavax, Inc. KH, RZ, SO,

332 DO, and LJ are employees of RTI Health Solutions, an independent research consultancy that received funding under a research

333 contract with Novavax, Inc. to conduct this study. The funder participated in the design and interpretation of the data and the

writing of this manuscript but had no role in the collection or analysis of the data or in the decision to publish these results.

Legal Disclosure: Registered and proprietary names, e.g., trademarks, used herein are not to be considered unprotected by law
 even when not specifically marked as such.

337 References

338	1.	Food and Drug Administration. Comirnaty. Available online:
339		https://www.fda.gov/vaccines-blood-biologics/comirnaty (accessed on 23 May 2024).
340	2.	Food and Drug Administration. Spikevax. Available online:
341		https://www.fda.gov/vaccines-blood-biologics/spikevax (accessed on 24 May 2024).
342	3.	Health Canada. Approved COVID-19 Vaccines. Available online:
343		https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-vaccines-treat
344		ments/vaccines.html (accessed on 30 May 2024).
345	4.	Food and Drug Administration. Novavax COVID-19 Vaccine, Adjuvanted. Available online:
346		https://www.fda.gov/vaccines-blood-biologics/coronavirus-covid-19-cber-regulated-biologics/novavax-covid-19
347		<u>-vaccine-adjuvanted</u> (accessed on 24 May 2024).
348	5.	Anez, G.; Dunkle, L.M.; Gay, C.L.; Kotloff, K.L.; Adelglass, J.M.; Essink, B.; Campbell, J.D.; Cloney-Clark, S.; Zhu,
349		M.; Plested, J.S.; et al. Safety, Immunogenicity, and efficacy of the NVX-CoV2373 COVID-19 vaccine in
350		adolescents: A randomized clinical trial. JAMA Netw. Open 2023, 6, e239135,
351		doi:10.1001/jamanetwork open.2023.9135.
352	6.	Baden, L.R.; El Sahly, H.M.; Essink, B.; Kotloff, K.; Frey, S.; Novak, R.; Diemert, D.; Spector, S.A.; Rouphael, N.;
353		Creech, C.B.; et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 2021, 384,
354		403–416, doi:10.1056/NEJM0a2035389.
355	7.	Dunkle, L.M.; Kotloff, K.L.; Gay, C.L.; Anez, G.; Adelglass, J.M.; Barrat Hernandez, A.Q.; Harper, W.L.;
356		Duncanson, D.M.; McArthur, M.A.; Florescu, D.F.; et al. Efficacy and safety of NVX-CoV2373 in adults in the
357		United States and Mexico. N. Engl. J. Med. 2022 , 386, 531–543, doi:10.1056/NEJM0a2116185.
358	8.	Heath, P.T.; Galiza, E.P.; Baxter, D.N.; Boffito, M.; Browne, D.; Burns, F.; Chadwick, D.R.; Clark, R.; Cosgrove, C.;
359		Galloway, J.; et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med. 2021, 385, 1172–1183,
360		doi:10.1056/NEJMoa2107659.
361	9.	Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Perez Marc, G.; Moreira,
362		E.D.; Zerbini, C.; et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 2020, 383,
363		2603–2615, doi:10.1056/NEJMoa2034577.
364	10.	Alves, K.; Plested, J.S.; Galbiati, S.; Chau, G.; Cloney-Clark, S.; Zhu, M.; Kalkeri, R.; Patel, N.; Smith, K.;
365		Marcheschi, A.; et al. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373. Vaccine 2023,
366		41, 4280–4286, doi:10.1016/j.vaccine.2023.05.051.
367	11.	Sadoff, J.; Gray, G.; Vandebosch, A.; Cardenas, V.; Shukarev, G.; Grinsztejn, B.; Goepfert, P.A.; Truyers, C.;
368		Fennema, H.; Spiessens, B.; et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. N.
369		Engl. J. Med. 2021 , 384, 2187–2201, doi:10.1056/NEJMoa2101544.
370	12.	San Francisco Ramos, A.; Liu Sanchez, C.; Bovill Rose, T.; Smith, D.; Thorn, N.; Galiza, E.; Miah, T.; Pearce, J.;
371		Hultin, C.; Cosgrove, C.; et al. Comparing reactogenicity of COVID-19 vaccine boosters: A systematic review and
372		meta-analysis. Expert Rev. Vaccines 2024 , 23, 266–282, doi:10.1080/14760584.2024.2315089.
373	13.	Centers for Disease Control and Prevention. Seasonal Influenza Vaccine Safety: A Summary for Clinicians.
374		Available online: https://www.cdc.gov/flu/professionals/vaccination/vaccine_safety.htm (accessed on 4 June
375		2024).
376	14.	Centers for Disease Control and Prevention. Shingles: About the Vaccine. Available online:
377		https://www.cdc.gov/vaccines/vpd/shingles/hcp/shingrix/about-vaccine.html (accessed on 4 June 2024).

378	15.	Gonen, T.; Barda, N.; Asraf, K.; Joseph, G.; Weiss-Ottolenghi, Y.; Doolman, R.; Kreiss, Y.; Lustig, Y.;
379		Regev-Yochay, G. Immunogenicity and reactogenicity of coadministration of COVID-19 and influenza vaccines.
380		JAMA Netw. Open 2023 , 6, e2332813, doi:10.1001/jamanetworkopen.2023.32813.
381	16.	Werner, F.; Zeschick, N.; Kuhlein, T.; Steininger, P.; Uberla, K.; Kaiser, I.; Sebastiao, M.; Hueber, S.; Warkentin, L.
382		Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative
383		observational cohort study. BMC Med. 2023, 21, 358, doi:10.1186/s12916-023-03064-6.
384	17.	Rousculp, M.D.; Hollis, K.; Ziemiecki, R.; Odom, D.; Marchese, A.M.; Montazeri, M.; Odak, S.; Jackson, L.; Miller,
385		A.; Toback, S. Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United
386		States and Canada: Results from a prospective observational study. Vaccines (Basel) 2024, 12,
387		doi:10.3390/vaccines12010083.
388	18.	Breeher, L.E.; Wolf, M.E.; Geyer, H.; Brinker, T.; Tommaso, C.; Kohlnhofer, S.; Hainy, C.; Swift, M. Work absence
389		following COVID-19 vaccination in a cohort of healthcare personnel. J. Occup. Environ. Med. 2022, 64, 6–9,
390		doi:10.1097/JOM.0000000002376.
391	19.	Nachtigall, I.; Bonsignore, M.; Hohenstein, S.; Bollmann, A.; Gunther, R.; Kodde, C.; Englisch, M.; Ahmad-Nejad,
392		P.; Schroder, A.; Glenz, C.; et al. Effect of gender, age and vaccine on reactogenicity and incapacity to work after
393		COVID-19 vaccination: A survey among health care workers. BMC Infect. Dis. 2022, 22, 291,
394		doi:10.1186/s12879-022-07284-8.
395	20.	Costa, K. Older Adults' Intentions and Attitudes Toward the Updated Bivalent COVID-19 Booster 2023: Survey,
396		United States, July 2023. Available online:
397		https://www.healthcanal.com/health/the-bivalent-covid-19-booster-survey (accessed on 30 May 2024).
398	21.	Rief, W. Fear of adverse effects and COVID-19 vaccine hesitancy: Recommendations of the treatment expectation
399		expert group. JAMA Health Forum 2021, 2, e210804, doi:10.1001/jamahealthforum.2021.0804.
400	22.	Freeman, E.E.; Strahan, A.G.; Smith, L.R.; Judd, A.D.; Samarakoon, U.; Chen, G.; King, A.J.; Blumenthal, K.G. The
401		impact of COVID-19 vaccine reactions on secondary vaccine hesitancy. Ann Allergy Asthma Immunol 2024,
402		doi:10.1016/j.anai.2024.01.009.
403	23.	Tiozzo, G.; Louwsma, T.; Konings, S.R.A.; Vondeling, G.T.; Perez Gomez, J.; Postma, M.J.; Freriks, R.D.
404		Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses. Expert Rev. Vaccines 2023, 22,
405		410–418, doi:10.1080/14760584.2023.2208216.
406	24.	National Foundation for Infectious Diseases 2023 National Survey: Attitudes about Influenza, COVID-19,
407		Respiratory Syncytial Virus, and Pneumococcal Disease. Available online:
408		https://www.nfid.org/resource/2023-national-survey-attitudes-about-influenza-covid-19-respiratory-syncytial-vi
409		<u>rus-and-pneumococcal-disease/</u> (accessed on 12 March 2024).
410	25.	Marchese, A.M.; Rousculp, M.; Macbeth, J.; Beyhaghi, H.; Seet, B.T.; Toback, S. The Novavax heterologous
411		COVID booster demonstrates lower reactogenicity than mRNA: A targeted review. J. Infect. Dis. 2023,
412		doi:10.1093/infdis/jiad519.
413	26.	Munro, A.P.S.; Janani, L.; Cornelius, V.; Aley, P.K.; Babbage, G.; Baxter, D.; Bula, M.; Cathie, K.; Chatterjee, K.;
414		Dodd, K.; et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two
415		doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised,
416		controlled, phase 2 trial. Lancet 2021, 398, 2258-2276, doi:10.1016/S0140-6736(21)02717-3.
417	27.	Atmar, R.L.; Lyke, K.E.; Deming, M.E.; Jackson, L.A.; Branche, A.R.; El Sahly, H.M.; Rostad, C.A.; Martin, J.M.;
418		Johnston, C.; Rupp, R.E.; et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med.
419		2022 , 386, 1046–1057, doi:10.1056/NEJMoa2116414.

420	28.	Sutton, N.; San Francisco Ramos, A.; Beales, E.; Smith, D.; Ikram, S.; Galiza, E.; Hsia, Y.; Heath, P.T. Comparing
421		reactogenicity of COVID-19 vaccines: A systematic review and meta-analysis. Expert Rev. Vaccines 2022, 21,
422		1301–1318, doi:10.1080/14760584.2022.2098719.
423	29.	Salter, S.M.; Li, D.; Trentino, K.; Nissen, L.; Lee, K.; Orlemann, K.; Peters, I.; Murray, K.; Leeb, A.; Deng, L. Safety
424		of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: A prospective cohort study of Australian
425		community pharmacy vaccinations. Vaccines (Basel) 2022, 10, doi:10.3390/vaccines10122017.
426	30.	Stuart, A.S.V.; Shaw, R.H.; Liu, X.; Greenland, M.; Aley, P.K.; Andrews, N.J.; Cameron, J.C.; Charlton, S.;
427		Clutterbuck, E.A.; Collins, A.M.; et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19
428		primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2):
429		a single-blind, randomised, phase 2, non-inferiority trial. Lancet 2022, 399, 36–49,
430		doi:10.1016/S0140-6736(21)02718-5.
431	31.	Shaw, R.H.; Stuart, A.; Greenland, M.; Liu, X.; Nguyen Van-Tam, J.S.; Snape, M.D.; Com, C.O.V.S.G.
432		Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. Lancet 2021, 397, 2043–2046,
433		doi:10.1016/S0140-6736(21)01115-6.
434	32.	European Medicines Agency. EMA Recommendation to Update the Antigenic Composition of Authorised
435		COVID-19 Vaccines for 2024-2025. Available online:
436		https://www.ema.europa.eu/en/documents/other/ema-recommendation-update-antigenic-composition-authoris
437		ed-covid-19-vaccines-2024-2025_en.pdf (accessed on 26 May 2024).
438	33.	World Health Organization. Statement on the Antigen Composition of COVID-19 Vaccines. Available online:
439		https://www.who.int/news/item/26-04-2024-statement-on-the-antigen-composition-of-covid-19-vaccines
440		(accessed on 26 May 2024).
441	34.	Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall
442		2023. Available online:
443		https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023
444		(accessed on 26 May 2024).
445	35.	Food and Drug Administration. Vaccines and Related Biological Products Advisory Committee June 5, 2024
446		Meeting Announcement. Available online:
447		https://www.fda.gov/advisory-committees/advisory-committee-calendar/vaccines-and-related-biological-produ
448		<u>cts-advisory-committee-june-5-2024-meeting-announcement</u> (accessed on 26 May 2024).
449		